{
    "clinical_study": {
        "@rank": "78951", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "S0597 low dose", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "S0597 mid dose", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "S0597 high dose", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Comparator", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The study will assess the efficacy and safety of intranasal S0597 when compared to placebo\n      and active control in an environmental exposure unit model following 2 weeks of treatment"
        }, 
        "brief_title": "Efficacy and Safety of S0597 in Seasonal Allergic Rhinitis", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Seasonal Allergic Rhinitis", 
        "condition_browse": {
            "mesh_term": [
                "Rhinitis, Allergic, Seasonal", 
                "Rhinitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female participants aged 18 to 65 years with history of seasonal  allergic\n             rhinitis\n\n          -  Participants able to understand and willing to sign the informed consent form\n\n        Exclusion Criteria:\n\n          -  Anotomical deviations of the nasal septum that significantly impair ventilation or\n             airflow\n\n          -  Pregnant or nursing women\n\n          -  Positive serology for infectious disease (Hepatitis B or C, HIV) at screening\n\n          -  Parallel participation in another current investigational study, participation in a\n             study within less than 30 days prior to study entry, or previous participation in\n             this same study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "275", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01940146", 
            "org_study_id": "SPARC Ltd CLR_13_10"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "S0597 low dose", 
                "description": "S0597 low dose", 
                "intervention_name": "S0597 low dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "S0597 mid dose", 
                "description": "S0597 mid dose", 
                "intervention_name": "S0597 mid dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "S0597 high dose", 
                "description": "S0597 high dose", 
                "intervention_name": "S0597 high dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Comparator", 
                "description": "reference comparator", 
                "intervention_name": "Reference", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "September 6, 2013", 
        "location": {
            "contact": {
                "last_name": "Anne K Ellis, MD", 
                "phone": "613-548-2336"
            }, 
            "facility": {
                "address": {
                    "city": "Kingston", 
                    "country": "Canada"
                }, 
                "name": "Kingston General Hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "5", 
        "official_title": "Efficacy and Safety of Intranasal S0597 in an Environmental Exposure Unit Model of Seasonal Allergic Rhinitis: A Phase 2, Single-center, Randomized, Double-blind, Placebo and Active-controlled Parallel Group Study", 
        "overall_contact": {
            "last_name": "Anne K Elllis, MD", 
            "phone": "613-548-2336"
        }, 
        "overall_official": {
            "affiliation": "Kingston General Hospital", 
            "last_name": "Anne K Ellis, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in Total nasal symptom score from baseline to end of treatment at 2 weeks", 
            "measure": "Total nasal symptom score", 
            "safety_issue": "No", 
            "time_frame": "2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01940146"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Sun Pharma Advanced Research Company Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sun Pharma Advanced Research Company Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}